Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | TSPO | P30536 | 4/20 | 0.59 |
| ▸ | FABP4 | P15090 | 3/20 | 0.57 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.57 |
| ▸ | FABP3 | P05413 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20438537 | 0.88 | KDM4E (0.63) | KDM4EGLATSPOFABP4FABP5 | |
| SCHEMBL14003754 | 0.86 | KDM4E (0.73) | KDM4EGLATSPOFABP4FABP5 | |
| SCHEMBL150053 | 0.84 | KDM4E (1.00) | KDM4EGLATSPOFABP4FABP5 | |
| SCHEMBL29859932 | 0.84 | KDM4E (1.00) | KDM4EGLATSPOFABP4FABP5 | |
| SCHEMBL1128466 | 0.83 | KDM4E (0.68) | KDM4EGLATSPOFABP4FABP5 | |
| SCHEMBL28756439 | 0.83 | KDM4E (0.68) | KDM4EGLATSPOFABP4FABP5 | |
| SCHEMBL3322075 | 0.83 | KDM4E (0.68) | KDM4EGLATSPOFABP4FABP5 | |
| SCHEMBL3202252 | 0.78 | KDM4E (0.69) | KDM4EGLATSPOPOLB | |
| SCHEMBL31160335 | 0.78 | KDM4E (0.61) | KDM4EGLATSPOFABP4FABP5 | |
| SCHEMBL13957664 | 0.77 | MARK4 (0.53) | KDM4ETSPOPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841276-B2 | Fulvene and fulvalene analogs and their use in treating cancers | EMORY UNIVERSITY (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841276-B2 | Fulvene and fulvalene analogs and their use in treating cancers | EMORY UNIVERSITY (US) | 2014-09-23 | — | — | US | disclosed |
| WO-2008137740-A1 | FULVENE AND FULVALENE ANALOGS AND THEIR USE IN TREATING CANCERS | EMORY UNIVERSITY (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080275016-A1 | For drug resistant cancers; antiinflammatory agents;degenerative or vascular diseases; blocking nitrogen oxide so growth of tumors is suppressed | U.S. GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, THE | 2008-11-06 | — | — | US | disclosed |
| US-20080275016-A1 | For drug resistant cancers; antiinflammatory agents;degenerative or vascular diseases; blocking nitrogen oxide so growth of tumors is suppressed | U.S. GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, THE | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275016-A1 | For drug resistant cancers; antiinflammatory agents;degenerative or vascular diseases; blocking nitrogen oxide so growth of tumors is suppressed | NOX1, NOX3, ROS1 | KDM4E 1908/4885GLA 1308/4885TSPO 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.